Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12815284 | 0.85 | ESR1 (0.36) | — | |
| SCHEMBL30513708 | 0.84 | TAAR1 (0.36) | TAAR1KMT2ACYP2A13HTR6LMNA | |
| SCHEMBL21494784 | 0.84 | TAAR1 (0.36) | TAAR1KMT2ACYP2A13HTR6LMNA | |
| SCHEMBL18468779 | 0.80 | HTR7 (0.34) | TAAR1 | |
| SCHEMBL11066691 | 0.79 | HSPA5 (0.54) | TAAR1 | |
| SCHEMBL12944676 | 0.79 | TAAR1 (0.43) | TAAR1CYP2A13HTR6LMNAAR | |
| SCHEMBL12946192 | 0.79 | TAAR1 (0.43) | TAAR1CYP2A13HTR6SMN1; SMN2 | |
| SCHEMBL12816153 | 0.78 | TAAR1 (0.40) | TAAR1ARALDH1A1 | |
| SCHEMBL12814675 | 0.78 | PYCR1 (0.36) | TAAR1KMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL12814879 | 0.78 | TAAR1 (0.43) | TAAR1KMT2AALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2691357-A1 | METHOD FOR PRODUCING 1-HEXENE | Sumitomo Chemical Company Limited (JP) | 2014-02-05 | — | — | EP | disclosed |
| US-20140012056-A1 | METHOD FOR PRODUCING 1-HEXENE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-09 | — | — | US | disclosed |
| WO-2012133937-A1 | METHOD FOR PRODUCING 1-HEXENE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140012056-A1 | METHOD FOR PRODUCING 1-HEXENE | AP2A1, AP1M1, ME1 | TAAR1 794/4885KMT2A 2582/4885CYP2A13 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.